Results 71 to 80 of about 5,144 (141)

Real-World Efficacy and Safety of Ixekizumab in the Treatment of Psoriasis: A Case-Series from Indian Sub-Continent. [PDF]

Indian J Dermatol
De A, Ahmed SS, Chakraborty D, Pal S.
europepmc   +1 more source

Real-world drug survival and treatment outcome of ixekizumab in patients with spondyloarthropathies. [PDF]

Front Immunol
Al-Awuad L, Al-Shammari M, Al-Dhayyan N, Alturaiki A.   +3 more
europepmc   +1 more source

Ixekizumab for genetically confirmed type 5 pityriasis rubra pilaris with a CARD14 p.Met119Thr variant. [PDF]

An Bras Dermatol
Tolun OF, Demir Y, Engin B.
europepmc   +1 more source

Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China. [PDF]

Chin Med J (Engl)
Jiang Y, Guo Z, Yao L, Huang D, Ma R, Zhong X, Wang Y, Lu J, Li Y, Shi Y.   +9 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Ixekizumab in Moderate-to-Severe Plaque Psoriasis in the Indian Population: A Pilot Study. [PDF]

Indian Dermatol Online J
Singh T, Srivastava S, Venugopal R, Agarwal R, Ranjan E, Gupta P.   +5 more
europepmc   +1 more source

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Zhang S, Lam T, Du Y, Chen X, Zhang H, Li L, Zhang G.   +6 more
europepmc   +1 more source

Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis. [PDF]

Dermatol Res Pract
Chaiyabutr C, Paringkarn T, Woramongkol T, Hutachoke T, Silpa-Archa N, Chularojanamontri L, Wongpraparut C.   +6 more
europepmc   +1 more source

Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study. [PDF]

Acta Derm Venereol
Nozaki H, Honma M, Fujita Y.
europepmc   +1 more source

IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence. [PDF]

Front Immunol
AbuJwaid YK, Assi AK, Amro AM, Awwad HH, Ehmidat M, Deeb S, Awlad Mohammad MW, Dwayat A, Odeh A, Albow Y, Yasini M, Alfrookh M, Alamlih L.   +12 more
europepmc   +1 more source

Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review. [PDF]

Immun Inflamm Dis
Pang M, Li L, Zhang Q, Zhao M.
europepmc   +1 more source